Long-Term Follow-up of Patients with Prostate Cancer and Nodal Metastases Treated by Pelvic Lymphadenectomy and Radical Prostatectomy: The Positive Impact of Adjuvant Radiotherapy

European Urology

Volumn 55, Issue 5, 2009, Pages 1003-1011

  Da Pozzo, Luigi F ^a   Cozzarini, Cesare ^a   Briganti, Alberto ^a   Suardi, Nazareno ^a   Salonia, Andrea ^a   Bertini, Roberto ^a   Gallina, Andrea ^a   Bianchi, Marco ^a   Fantini, Gemma V ^a   Bolognesi, Angelo ^a   Fazio, Ferruccio ^a   Montorsi, Francesco ^a   Rigatti, Patrizio ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Adjuvant radiotherapy; Lymph node metastases; Prostate cancer; Radical prostatectomy

Indexed keywords

GONADORELIN DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HORMONAL THERAPY; HUMAN; INTESTINE INJURY; LONG TERM CARE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PATIENT INFORMATION; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RETROSPECTIVE STUDY; TERTIARY HEALTH CARE; URETHRA STRICTURE;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; COHORT STUDIES; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PELVIS; PROPORTIONAL HAZARDS MODELS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 62649087473     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.01.046     Document Type: Article

References (30)

1. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
2. Freedland S.J., Partin A.W., Humphreys E.B., Mangold L.A., and Walsh P.C. Radical prostatectomy for clinical stage T3a disease. Cancer 109 (2007) 1273-1278
3. Yossepowitch O., Eggener S.E., Serio A.M., et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol 53 (2008) 950-959
4. Gontero P., Marchioro G., Pisani R., et al. Is radical prostatectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single-institution study. Eur Urol 51 (2007) 922-930 discussion 929-930
5. van den Ouden D., Davidson P.J., Hop W., and Schroder F.H. Radical prostatectomy as a monotherapy for locally advanced (stage T3) prostate cancer. J Urol 151 (1994) 646-651
6. Hsu C.-Y., Joniau S., Oyen R., Roskams T., and Van Poppel H. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol 51 (2007) 121-129 discussion 128-9
7. Briganti A., Chun F.K.-H., Salonia A., et al. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 49 (2006) 1019-1027 discussion 1026-7
8. Bader P., Burkhard F.C., Markwalder R., and Studer U.E. Is a limited lymph node dissection an adequate staging procedure for prostate cancer?. J Urol 168 (2002) 514-518 discussion 518
9. Heidenreich A., Ohlmann C.H., and Polyakov S. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 52 (2007) 29-37
10. Heidenreich A., Varga Z., and Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 167 (2002) 1681-1686
11. Allaf M.E., Palapattu G.S., Trock B.J., Carter H.B., and Walsh P.C. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 172 (2004) 1840-1844
12. Cheng L., Zincke H., Blute M.L., Bergstralh E.J., Scherer B., and Bostwick D.G. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 91 (2001) 66-73
13. Palapattu G.S., Allaf M.E., Trock B.J., Epstein J.I., and Walsh P.C. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup. J Urol 172 (2004) 1860-1864
14. Bader P., Burkhard F.C., Markwalder R., and Studer U.E. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?. J Urol 169 (2003) 849-854
15. Daneshmand S., Quek M.L., Stein J.P., et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 172 (2004) 2252-2255
16. Boorjian S.A., Thompson R.H., Siddiqui S., et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 178 (2007) 864-870 discussion 870-1
17. Briganti A., Karnes J.R., Da Pozzo L.F., et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 55 (2009) 261-270
18. Schumacher M.C., Burkhard F.C., Thalmann G.N., Fleischmann A., and Studer U.E. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 54 (2008) 344-352
19. Bolla M., van Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366 (2005) 572-578
20. Thompson Jr. I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296 (2006) 2329-2335
21. Coen J.J., Zietman A.L., Thakral H., and Shipley W.U. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol 20 (2002) 3199-3205
22. Bochner B.H., Herr H.W., and Reuter V.E. Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens. J Urol 166 (2001) 2295-2296
23. Cozzarini C., Bolognesi A., Ceresoli G.L., et al. Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: a single institute experience of 415 patients. Int J Radiat Oncol Biol Phys 59 (2004) 674-683
24. Zelefsky M.J., Aschkenasy E., Kelsen S., and Leibel S.A. Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 39 (1997) 327-333
25. Cozzarini C., Fiorino C., Ceresoli G.L., et al. Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy). Int J Radiat Oncol Biol Phys 55 (2003) 688-694
26. Marks L.B., Carroll P.R., Dugan T.C., and Anscher M.S. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys 31 (1995) 1257-1280
27. Catalona W.J., Smith D.S., Ratliff T.L., and Basler J.W. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270 (1993) 948-954
28. Kattan M.W. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 95 (2003) 634-635
29. Lawton C.A., Winter K., Grignon D., and Pilepich M.V. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol 23 (2005) 800-807
30. Messing E.M., Manola J., Yao J., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7 (2006) 472-479